Clinical trials
Recurrent Ovarian Cancer clinical trials
Below are recruiting recurrent ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 226 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05128825RecruitingPhase 2
Azenosertib for platinum-resistant ovarian cancer with cyclin e1
This trial tests a new pill called azenosertib (ZN-c3) for ovarian cancer that stopped responding to platinum chemotherapy. The drug targets tumors with high levels of the Cyclin E1 protein, and the goal is to see if it can shrink tumors or slow the cancer's growth.
Mobile, AlabamaAges 18 years+ - NCT06303505RecruitingPhase 1/Phase 2
TUB-040 for advanced ovarian or lung cancer after standard treatments fail
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
Birmingham, AlabamaAges 18 years+ - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT05559879RecruitingPhase 1/Phase 2
Cabozantinib and dostarlimab for recurrent gynecologic carcinosarcoma
This trial tests the combination of cabozantinib and dostarlimab to treat recurrent (coming back) gynecologic carcinosarcoma, after standard chemotherapy has already been tried. It aims to shrink tumors and improve outcomes by targeting cancer pathways.
Birmingham, AlabamaAges 18 years+ - NCT02543710RecruitingPhase 4
Biomarker-guided treatment for endometrial cancer
This study uses a tumor “biomarker” test to guide treatment in people with endometrial cancer (and sometimes epithelial ovarian cancer). It tests whether tailoring weekly chemotherapy (paclitaxel) based on biomarker levels can help patients, especially when the cancer has come back or is advanced.
NijmegenAges 18–95 - NCT05401162Recruiting
Chemo with your own stem cells for ovarian cancer
This study looks at giving chemotherapy with an added support step using your own collected stem cells. It may help people with recurrent or metastatic ovarian cancer by supporting bone marrow recovery while treatment continues.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT04486352RecruitingPhase 1/Phase 2
Targeted therapy trial for recurrent or persistent endometrial cancer
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
Duarte, CaliforniaAges 18 years+ - NCT06504147RecruitingPhase 2
Radspherin for ovarian cancer with peritoneal spread
This trial tests a radioactive treatment called Radspherin given during surgery for advanced ovarian cancer that has spread to the lining of the abdomen. It is for people whose tumors are HR proficient (a specific genetic type) and who have already had chemotherapy before surgery.
Tampa, FloridaAges 18 years+ - NCT05983107RecruitingPhase 2
Chidamide/Everolimus for advanced breast cancer
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
Beijing, Beijing MunicipalityAges 18–75 - NCT05172310RecruitingPhase 1
PET scan study using a new tracer for solid tumors
This trial tests a special PET/CT scan using a new tracer (68Ga-FAPI) to help show tumors in the pancreas, bile ducts, stomach, or certain ovarian cancers. It may help doctors better see where cancer is in preparation for surgery or biopsy.
StockholmAges 19 years+ - NCT04518501RecruitingPhase 1/Phase 2
Testing fuzuloparib with arsenic and platinum for ovarian cancer
This early-phase study tests a combination of three medicines to treat ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum chemotherapy, especially when tumors have a BRCA1 or BRCA2 mutation. The goal is to see if this treatment can help control cancer that is hard to treat.
Zhejiang, HangzhouAges 18–70 - NCT07593092RecruitingPhase 1
Testing new cancer immunotherapy for advanced ovarian cancer
This study tests two new experimental drugs (XmAb541 and XmAb808) designed to fight advanced ovarian cancer by activating your immune system. You'll be closely monitored to see how safe the drugs are and how your body tolerates them.
Lake Success, New YorkAges 18 years+ - NCT06844136Recruiting
ChemoINTEL test study for ovarian cancer
This study is testing a new lab test (called ChemoINTEL) that looks at how your cancer cells respond to chemotherapy drugs used for ovarian cancer. The goal is to see if the test can predict how well the treatment will work for you.
Liverpool, MerseysideAges 18 years+ - NCT06971744RecruitingPhase 2
Study of autophagy maintenance for ovarian cancer
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
Charleston, South CarolinaAges 18 years+ - NCT06730347RecruitingPhase 2
Study of lorigerlimab for advanced ovarian and other cancers
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT04644289RecruitingPhase 2
Olaparib plus durvalumab for early testing in ovarian cancer
This study tests whether olaparib and durvalumab given around the time of diagnosis can help people with advanced ovarian cancer. It also strongly focuses on collecting tumor and blood samples to better understand who may benefit.
Mannheim, Baden-WurttembergAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT07741968Recruiting
Online program to ease fear of cancer returning
This study tests an online program designed to help women with advanced or certain types of breast or gynecologic cancer manage their fear of the disease progressing or returning. The program aims to reduce anxiety and improve quality of life.
Arcadia, CaliforniaAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT07498478RecruitingPhase 2
Tinengotinib and fulvestrant for advanced HR+ HER2- breast cancer
This trial tests a new drug called tinengotinib combined with the hormone therapy fulvestrant for people with HR-positive, HER2-negative breast cancer that has come back or spread. It is for those who have already tried a CDK4/6 inhibitor and at least one hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05487092Recruiting
Letrozole to help prevent endometrioma coming back after surgery
This study tests whether taking letrozole after laparoscopic ovarian cyst surgery can lower the chance that an endometrioma (a type of ovarian endometriosis cyst) comes back. It may help some people reduce recurrence after the cyst is removed.
Hong KongAges 18–45 - NCT05875155Recruiting
Saving eggs by freezing ovarian tissue during cancer or surgery care
This trial looks at freezing ovarian tissue to help protect future fertility for people who may lose ovarian function from medical treatments or ovarian surgery. It may help you preserve the chance to have children later when egg or embryo freezing alone isn’t an option.
Pittsburgh, PennsylvaniaAges Up to 39 years
Hear when a new Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent ovarian cancer?
- Yes. Clin2 currently lists 226 recruiting recurrent ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.